SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Reports that NYSE/ICE is testing Avalanche for a 24/7 tokenized-securities platform, along with expanded broker access, are fueling attention around AVAX and its recent rebound. Traders are divided between viewing the institutional and real-world-asset narrative as a durable catalyst and dismissing the move as another short-lived pump amid concerns about weak demand, inflation, and repeated selloffs.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is drawing attention after traders linked its sharp rally to the launch of confidential perpetual contracts powered by Hyperliquid, alongside broader enthusiasm for its AI-agent, privacy, and cross-chain infrastructure. Sentiment is largely bullish, though some traders argue the move is primarily liquidity-driven and warn of a pullback or speculative pump.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Escalating U.S.-Iran tensions, Strait of Hormuz shipping disruptions, and attacks on Saudi energy infrastructure are sustaining a geopolitical supply-risk premium in crude and driving attention to XLE. Traders remain divided between continued energy strength if disruptions persist and a pullback if diplomacy or restored flows ease oil prices, with technical breakout and profit-taking discussions adding to the debate.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Reports of a multimillion-dollar exploit involving Hedera-based Sauce/Bonzo DeFi protocols are driving renewed attention, with traders debating whether the incident will weigh on HBAR. Some argue Hederas core network was not compromised and remain focused on long-term adoption, while others point to the hack, token dilution, and regulatory uncertainty as reasons for continued weakness.

Daily surprises, near and far. Your source for travel inspiration and more. Travel moves you!

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Attention is centered on reports that Paramount Skydance and California officials are in advanced settlement talks over the antitrust case challenging the proposed acquisition of Warner Bros. Traders view a settlement as improving the deals closing prospects, while others remain concerned that negotiations could fail and leave WBD exposed to significant merger and litigation risk.

the cat on Base  community-run home for $BASECAT

Basecat

Attention is centered on Basecats volatile trading following its Coinbase listing, with traders focused on elevated volume, selling pressure, and the sharp pullback after an earlier pump. The community is split between dip buyers expecting a reversal and skeptics calling it a pump-and-dump with further downside risk.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

A sharp rebound with heavier volume has fueled breakout speculation around Chainlink, with traders pointing to its role in tokenization, CCIP, and institutional blockchain adoption alongside ongoing Clarity Act discussion. Others remain skeptical, citing weak price performance, token-supply concerns, and uncertainty over whether network adoption translates into value for LINK.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Elevated oil and jet-fuel prices tied to Middle East tensions are driving the main debate around Delta, with traders weighing margin pressure against resilient premium travel demand and the companys ability to pass higher costs through to fares. Bulls view Deltas pricing power and refinery exposure as cushioning the fuel shock, while bears expect sustained energy costs to trigger further volatility and earnings pressure.

TOSHI

Speculation around a pending project announcement and possible expansion or listings across Base, Robinhood, or Binance is driving attention, alongside increased volume and repeated calls for a technical breakout. Sentiment is divided: bullish holders anticipate a squeeze and ecosystem-driven rally, while others point to weak volume, repeated resistance, and broader crypto-market weakness.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

CEO Rene Haass confidence that Arm can convert strong demand for its AGI/data-center CPU into revenue has fueled renewed interest, amplified by a broader semiconductor rebound. Traders are split between bullish AI-infrastructure and server-CPU momentum versus concerns that Arms valuation is excessive and the stock is facing technical resistance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE) PR Newswire NEW YORK, Aug. 24, 2026 NEW YORK, Aug. 24, 2026...

Small Cap Stocks To Follow Now - May 3rd

Inflection Point Acquisition Corp. II, Direxion Daily MU Bull 2X Shares, and Cue Biopharma are the three Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of publicly traded companies with relatively small market capitalizationstypically ro...

Cue Biopharma (NASDAQ:CUE) Downgraded to Buy Rating by Wall Street Zen

Wall Street Zen lowered Cue Biopharma from a "strong-buy" rating to a "buy" rating in a research note on Sunday...

Small Cap Stocks To Follow Now - May 2nd

Inflection Point Acquisition Corp. II, Direxion Daily MU Bull 2X Shares, Cue Biopharma, Esperion Therapeutics, and Akanda are the five Small Cap stocks to watch today, according to MarketBeat's stock...

Top Small Cap Stocks To Add to Your Watchlist - May 1st

This Market Is Moving Fast

The market is sending a clear signal: capital is flowing aggressively into platforms that can scale innovation, whether that’s next-generation immunotherapy, AI-driven digital ecosystems, or entirely new infrastructure for energy and materials. This week’s developments, from fresh biotech funding to explosive user growth in social platforms and bold pivots into clean energy, highlight a broader theme: investors are rewarding companies that are either accelerating commercialization or positioning themselves at critical bottlenecks in emerging industries. $CUE, $RDDT, $SOBR, $KBLB, $WTO, $AKAN

Nasdaq, S&P 500 Futures Take A Breather Near Highs: Why AAPL, META, RDDT, RBLX, CUE Are Keeping Traders Engaged Today

Equity

Data from Stocktwits shows that retail traders are bullish on SPY and QQQ again.


Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving?

Cue Biopharma Inc. shares surged 67.57% after announcing a $30M financing, anti-IgE antibody license, and new CEO.read more...

CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? 

The company announced a $30 million private placement, licensed a new clinical-stage drug candidate, and appointed a new CEO.


Cue Biopharma (NASDAQ:CUE) Raised to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Cue Biopharma from a "buy" rating to a "strong-buy" rating in a research note on Saturday...

• Reported GAAP EPS of -$24.14 down -804.12% YoY
• Reported revenue of $7.88M up 166.66% YoY
• Cue Biopharma, Inc. believes that its cash and cash equivalents on hand as of June 30, 2026, along with the net proceeds from the July 2026 private placement, will be sufficient.

Cue Biopharma, Inc. faces significant risks including a history of operating losses, dependence on successful clinical development of drug candidates, and potential limitations in accessing clinical trial data from China.

Cue Biopharma, Inc. is advancing a portfolio of transformative therapies using its Immuno-STAT platform and has secured significant additional capital to fund its research and development and ongoing operations.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its pipeline includes CUE-221, a novel anti-IgE antibody with a dual mechanism of action, and CUE-401, designed to regulate inflammation and drive Treg-mediated tolerance. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Microsoft Corp

Meta Platforms Inc

SELLAS Life Sciences Group Inc

Alphabet Inc Class A

CoreWeave Inc

SpaceX

Stocktwits Polls

$CUE Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint 
 
Cue Biopharma announced positive topline results from the Phase 2 clinical trial of CUE-221 conducted in China by Genesis Life Sciences, a related company of Ascendant Health Limited. The trial enrolled 145 participants with moderate to severe chronic spontaneous urticaria, a disease resulting in chronic hives, that remained inadequately controlled despite treatment with H1 antihistamines. Key Highlights: Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profile; Clinically different efficacy profile observed relative to XOLAIR highlights potential for a fundamental mechanism-based biological difference.

DonCorleone77

$CUE …the $HORTS are  starting to run and look a lot like far as Gump…RUN Forrest RUN😂… right through the end zone… $100 price target‼️

da printa

$CUE faces a shareholder investigation by Purcell & Lefkowitz LLP over alleged fiduciary breaches.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CUE Cue Biopharma Inc

Fundamentals

Latest CUE News